Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Sarepta Therapeutics Inc. currently has 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 7 distinct examiners, which indicates that each active matter is being reviewed by a different individual. This distribution suggests that the company's Biotechnology & Pharmaceuticals prosecution strategy involves managing multiple separate examiner relationships simultaneously.
The pending office actions are categorized into 4 distinct art units, showing some technical concentration despite the variety of examiners involved. DHAR, MATASHA is identified as the busiest examiner for the company, holding 1 busiest examiner pending action. Because there are 4 distinct art units for the total actions, DHAR, MATASHA handles a minority of the overall workload. The presence of 1 busiest examiner pending action suggests that while the examiners are unique, their technical focus is grouped into a smaller number of specialized units within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DHAR, MATASHA | 1 | 43.3% | +45.7% |
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17348515 | Adeno-Associated Virus Vector Delivery for Muscular Dystrophies | GONZALES, JOSEPHINE MARIA | 13d |
| 18181271 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18022059 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | MCCORMICK, CATHERINE LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17348515 | Adeno-Associated Virus Vector Delivery for Muscular Dystrophies | GONZALES, JOSEPHINE MARIA | 13d |
| 18680380 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | DHAR, MATASHA | — |
| 18634360 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | VYAS, KEYUR ANILKUMAR | — |
| 18500627 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | VANHORN, ABIGAIL LOUISE | — |
| 18257547 | COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY | CHONG, KIMBERLY | — |
| 18181271 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18022059 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1636 | 2 |
| 1638 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18680380 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | DHAR, MATASHA | — | §112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18634360 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | VYAS, KEYUR ANILKUMAR | 1637 | §103DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18500627 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18257547 | COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY | CHONG, KIMBERLY | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Jun 14, 2023 |
| 18181271 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §101§103DPOther | Non-Final OA | — | Pending | Mar 09, 2023 |
| 18022059 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | MCCORMICK, CATHERINE LYNN | 1638 | §101DPOther | Non-Final OA | — | Pending | Feb 17, 2023 |
| 17348515 | Adeno-Associated Virus Vector Delivery for Muscular Dystrophies | GONZALES, JOSEPHINE MARIA | 1631 | DP | Final Rejection | 13d | Pending | Jun 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial